Press Releases
-
Dec 9, 2008
BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan(R) (sapropterin dihydrochloride)...
-
Nov 25, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York...
-
Nov 21, 2008
BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with...
-
Nov 6, 2008
BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA...
-
Nov 5, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse 2008 Annual Healthcare Conference...
-
Nov 3, 2008
BioMarin Pharmaceutical Inc. announced today the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS...
-
Oct 28, 2008Well-Positioned for Continued Long-Term Growth
Financial Highlights ($ in millions, except per share data) Item Q3 2008 Q3 2007 Comparison Total BioMarin Revenue $72.6 190.5% increase Naglazyme Net Product Revenue $33.3 56.3% increase...
-
Oct 15, 2008Subjects Show Improvement in Endothelial Dysfunction
BioMarin Pharmaceutical Inc. today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in patients with sickle cell disease (SCD) designed to...
-
Oct 7, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 28, at 5:00 p.m. ET (23:00...
-
Oct 7, 2008
BioMarin Pharmaceutical Inc. announced today that it has opened a new office in Brisbane, California, to expand its drug development operations and better meet the increasing demands of the...
-
Sep 25, 2008Decision on Marketing Authorization Expected by End of 2008
BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride)...
-
Sep 18, 2008
BioMarin Pharmaceutical Inc. announced today several corrections to an article released by Bloomberg this morning. The article was based on a telephone interview with Jean-Jacques Bienaime, Chief...
-
Sep 11, 2008
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global...
-
Sep 2, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...
-
Sep 2, 2008
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 3rd Annual Citi Biotech Day in New York City on...
-
Aug 21, 2008Conference Call and Webcast to Be Held Today at 4:30 p.m. ET (21:30 CET)
BioMarin Pharmaceutical Inc. announced today the roll-out of the national PKU Demographics, Outcomes and Safety Registry (PKUDOS). The registry is open to all PKU clinics within the United States,...
-
Aug 5, 2008Second Quarter Profit Driven by Strong Revenue Growth Improved Total Revenue Guidance
Financial Highlights ($ in millions, except per share data) Item Q2 2008 Q2 2007 Comparison Total BioMarin Revenue $64.2 122% increase Naglazyme Net Product Revenue $35.1 67.9% increase Aldurazyme...
-
Jul 22, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summit's novel...
-
Jul 16, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo), has received marketing approval from the Japanese Ministry of...
-
Jul 15, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 5,...
-
Jul 1, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Collins Stewart Growth...
-
Jun 5, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio...
-
May 22, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) will host a Research and Development Day for the financial community on Thursday, June 5, 2008 from 7:30 a.m. to 11:30 a.m. at the W New York...
-
May 20, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine...
-
May 7, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Healthcare...
-
May 6, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...
-
Apr 29, 2008First Quarter Profit Driven by Strong Revenue Growth
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the first quarter ended March 31, 2008. Net income was $1.7 million ($0.02 per share) for the first...
-
Apr 24, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global...
-
Apr 8, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, April 29,...
-
Mar 31, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing...
-
Mar 12, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Lehman Brothers Global...
-
Mar 11, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...
-
Mar 11, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jeff Cooper, Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 28th Annual...
-
Feb 26, 2008Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2007. Net income was $2.6 million ($0.03 per share)...
-
Feb 5, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February...
-
Jan 30, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 19th Annual Merrill Lynch...
-
Jan 28, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today the appointment of Dr. Gordon Vehar as Vice President of Research. Former Vice President of Research and Development for Raven...
-
Jan 23, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wachovia Healthcare...
-
Jan 22, 2008
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has appointed Mr. Steve Glass as Vice President and General Manager of European Operations. BioMarin Europe Ltd.,...
-
Jan 3, 2008BioMarin will Continue to Manufacture; Genzyme will Continue to Market and Sell Aldurazyme
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Genzyme Corporation announced today a restructuring of their joint venture regarding Aldurazyme(R) (laronidase). Under the revised...
-
Dec 18, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has re-acquired the Canadian rights for tetrahydrobiopterin (BH4), including Kuvan(TM) (sapropterin dihydrochloride),...
-
Dec 13, 2007First Specific Drug Therapy Approved for the Treatment of PKU
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride)...
-
Dec 3, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced today that they have initiated a program to develop an IgA protease for treating IgA nephropathy. IgA proteases...
-
Nov 27, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL...
-
Nov 8, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has submitted the Marketing Authorization...
-
Nov 6, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Annual...
-
Nov 1, 2007Increased Aldurazyme and Naglazyme Revenue Contribute to Reduced Net Loss
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the third quarter ended September 30, 2007. The net loss was $5.2 million ($0.05 per share) for the third...
-
Oct 31, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Rodman & Renshaw 9th...
-
Oct 24, 2007Financial Assistance Intended To Help Patients with Out of Pocket Expenses for Medical Foods
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has provided a $250,000 grant to the National Organization for Rare Disorders (NORD) to support a new financial...
-
Oct 18, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November...
-
Oct 17, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that data from clinical studies of Kuvan(TM) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase), and Aldurazyme(R)...
-
Sep 27, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that a systematic literature review and meta-analysis of blood phenylalanine (Phe) levels and clinical outcomes in...
-
Sep 17, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual...
-
Sep 4, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Bear Stearns 20th Annual...
-
Aug 30, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the BioCentury NewsMakers in...
-
Aug 22, 2007Molecular Chaperones Target Underlying Defect in Cystic Fibrosis; CFTR Folding and Transport
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds...
-
Aug 13, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has submitted a Biologics License...
-
Aug 13, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August...
-
Aug 7, 2007Continued Naglazyme Momentum Drives Record Revenues
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its second quarter ended June 30, 2007. The net loss was $3.9 million ($0.04 per share) for the second...
-
Jul 25, 2007PDUFA Date Set for November 25, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status to the New Drug...
-
Jul 24, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 7,...
-
Jun 18, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the first patient has initiated treatment in the expanded access program for Kuvan(TM) (sapropterin dihydrochloride), an...
-
Jun 12, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ 19th Investor...
-
May 29, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Health...
-
May 24, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Kuvan(TM) (sapropterin...
-
May 16, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Citigroup Global...
-
May 7, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman & Renshaw 4th...
-
May 2, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Baird Growth Stock...
-
May 2, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2a clinical study of 6R-BH4 (sapropterin dihydrochloride) for the...
-
Apr 30, 2007Q1 2007 Results Driven by Improved Naglazyme Sales - Raising Guidance
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its first quarter ended March 31, 2007. The net loss was $9.3 million ($0.10 per share) for the first...
-
Apr 23, 2007
BioMarin Pharmaceutical Inc. announced today that it closed the sale of $324,875,000 aggregate principal amount of its 1.875% Senior Subordinated Convertible Notes due 2017 (including $42,375,000...
-
Apr 19, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, May 2, at...
-
Apr 18, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has agreed to sell $282.5 million aggregate principal amount of its 1.875% senior subordinated convertible notes due...
-
Apr 16, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it intends to offer to sell, subject to market and other conditions, $250 million aggregate principal amount of senior...
-
Mar 12, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Lehman Brothers Tenth...
-
Mar 6, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Cowen and Company 27th...
-
Feb 20, 2007No Significant Difference Observed Between 6R-BH4 and Placebo
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results from its Phase 2a placebo-controlled double-blind study of 6R-BH4 in patients with poorly controlled hypertension....
-
Feb 20, 2007Positive Outlook for 2007 Driven by Increasing Revenue and Advancing Product Pipeline
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its fourth quarter and year ended December 31, 2006. The net loss was $10.4 million ($0.11 per share) for...
-
Feb 16, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has changed the date and time of its fourth quarter and full year 2006 financial results conference call and webcast...
-
Feb 15, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February...
-
Jan 31, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Merrill Lynch Global...
-
Jan 29, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that in response to the previously announced call for redemption of its remaining $51.4 million aggregate principal outstanding...
-
Jan 16, 2007Phenoptin Significantly Increases Phenylalanine Tolerance in BH4-Responsive Patients; All Pre-Specified Endpoints Met
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the Phase 3 diet study of Phenoptin(TM) (sapropterin dihydrochloride), in combination with diet, in 4-12...
-
Jan 7, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the JPMorgan 25th Annual...
-
Jan 4, 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2 clinical study of 6R-BH4 for the treatment of symptomatic...
-
Dec 22, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) gave formal notice today that it is calling for redemption on January 26, 2007 (the Redemption Date), the remainder of its outstanding 3.50%...
-
Dec 18, 2006Data Confirms Safety and Efficacy of Phenoptin in PKU Patients; On Track to File NDA in Second Quarter 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the pivotal Phase 3 extension study of Phenoptin (sapropterin hydrochloride), an investigational oral...
-
Nov 2, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Cowen and Company 7th...
-
Nov 1, 2006Robust Naglazyme Launch Drives Better Bottom-Line Results
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its third quarter ended September 30, 2006. The net loss was $7.0 million ($0.08 per share) for the third quarter of...
-
Oct 31, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman and Renshaw 8th...
-
Oct 31, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Japan's Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Aldurazyme(R) (laronidase),...
-
Sep 25, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that 4 holders of its 3.50% Convertible Senior Subordinated Notes due 2008 have agreed to exchange $73.6 million in aggregate...
-
Sep 20, 2006Results Anticipated in the First Quarter of 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has completed enrollment of the Phase 2 clinical study of 6R-BH4 for the treatment of poorly controlled hypertension....
-
Sep 12, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) today announced data from clinical studies of Phenoptin(TM) (sapropterin dihydrochloride), an...
-
Sep 11, 2006Important Technical Hurdles Overcome - IND Filing Targeted for Late 2007
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that investigators presented data from preclinical studies of Phenylase(TM) (phenylalalanine ammonia lyase) that suggest the...
-
Aug 31, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at BioCentury's NewsMakers in the...
-
Aug 30, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Thomas Weisel Partners...
-
Aug 28, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA-approved orally disintegrating...
-
Aug 2, 2006Strong Naglazyme Sales Lead to Improved Top- and Bottom-Line Guidance for 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2006. The net loss was $1.3 million ($0.02 per share) for the second quarter of...
-
Jul 6, 2006
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2 clinical study of 6R-BH4 for the treatment of poorly controlled...